Verachem, LLC

Germantown, MD 20875

SBIR Award Summary

Total Number of Awards 16
Total Value of Awards $8.95MM
First Award Date 07/20/00
Most Recent Award Date 04/01/17

Key Personnel

Last Name Name Awards Contact
Gilson Michael K. Gilson 4
Potter Michael J Potter 4
Webb Simon Webb 8

16 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-09-220
Budget: 04/01/17 - 03/31/18

DESCRIPTION (provided by applicant): Host molecules, such as cyclodextrins and cucurbiturils, can 'capture' smaller molecules and affect their physical and chemical behavior. The stronger the host molecule holds onto, i.e. binds, its smaller 'guest' the larger the effect ca be. Host molecules themselves can also be chemically altered (i.e. deriv...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-09-220
Budget: 04/01/16 - 03/31/17

DESCRIPTION (provided by applicant): Host molecules, such as cyclodextrins and cucurbiturils, can 'capture' smaller molecules and affect their physical and chemical behavior. The stronger the host molecule holds onto, i.e. binds, its smaller 'guest' the larger the effect ca be. Host molecules themselves can also be chemically altered (i.e. deriv...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-09-220
Budget: 04/01/15 - 03/31/16

DESCRIPTION (provided by applicant): Host molecules, such as cyclodextrins and cucurbiturils, can 'capture' smaller molecules and affect their physical and chemical behavior. The stronger the host molecule holds onto, i.e. binds, its smaller 'guest' the larger the effect ca be. Host molecules themselves can also be chemically altered (i.e. deriv...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-09-220
Budget: 09/01/14 - 02/28/15

Project Summary Host molecules, such as cyclodextrins and cucurbiturils, can 'capture'smaller molecules and affect their physical and chemical behavior. The stronger the host molecule holds onto, i.e. binds, its smaller 'guest'the larger the effect can be. Host molecules themselves can also be chemically altered (i.e. derivatized), which can cha...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-07-160
Budget: 02/01/13 - 01/31/14

DESCRIPTION (provided by applicant): Many drugs are small molecules that act by binding to a specific protein and thus blocking or altering its actions. For example, the HIV protease inhibitors are important AIDS treatments that work by binding in the active site of the protease enzyme and preventing it from helping to make new viruses. When sci...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-07-160
Budget: 02/01/12 - 01/31/13

DESCRIPTION (provided by applicant): Many drugs are small molecules that act by binding to a specific protein and thus blocking or altering its actions. For example, the HIV protease inhibitors are important AIDS treatments that work by binding in the active site of the protease enzyme and preventing it from helping to make new viruses. When sci...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-07-160
Budget: 02/01/11 - 01/31/12

DESCRIPTION (provided by applicant): Many drugs are small molecules that act by binding to a specific protein and thus blocking or altering its actions. For example, the HIV protease inhibitors are important AIDS treatments that work by binding in the active site of the protease enzyme and preventing it from helping to make new viruses. When sci...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-07-160
Budget: 05/01/10 - 01/31/11

DESCRIPTION (provided by applicant): Many drugs are small molecules that act by binding to a specific protein and thus blocking or altering its actions. For example, the HIV protease inhibitors are important AIDS treatments that work by binding in the active site of the protease enzyme and preventing it from helping to make new viruses. When sci...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-03-119
Budget: 09/01/08 - 08/31/10

DESCRIPTION (provided by applicant): Discovering a compound that will bind a protein therapeutic target with high affinity, while retaining favorable pharmacological properties, can be a time-consuming and expensive bottleneck in the drug-discovery process. Computational methods can speed this ligand discovery step, but are not yet reliable enou...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-03-119
Budget: 09/01/07 - 08/31/08

DESCRIPTION (provided by applicant): Discovering a compound that will bind a protein therapeutic target with high affinity, while retaining favorable pharmacological properties, can be a time-consuming and expensive bottleneck in the drug-discovery process. Computational methods can speed this ligand discovery step, but are not yet reliable enou...

Load More